Source: International Congress 2017 – State of the art session: "Interstitial lung disease and pulmonary vascular diseases"
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bruno Crestani (Paris, France). IPF: a distinct clinical entity?. International Congress 2017 – State of the art session: "Interstitial lung disease and pulmonary vascular diseases"

Member's Comments

Mario Grage - 31.03.2018 07:28
good

Related content which might interest you: Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - CON Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - PRO Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 The pathogenesis of IPF: what is the latest paradigm? Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis Year: 2019 Unclassifiable interstitial lung disease: a distinct entity with heterogeneous progression Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 IPF: a morphological and biological entity Source: Annual Congress 2010 - PG1 Core Curriculum Postgraduate Course: Idiopathic pulmonary fibrosis Year: 2010 Combined pulmonary fibrosis and emphysema: A distinct entity? Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Chronic idiopathic cough: a discreet clinical entity? Source: Eur Respir J 2004; 24: Suppl. 48, 47s Year: 2004 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Clinical spectrum and outcome of non IPF patients with a typical UIP picture Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category? Source: Eur Respir J 2013; 42: 576-579 Year: 2013 IPF or NSIP? That is the question Source: Eur Respir J 2003; 22: 191-192 Year: 2003 Interstitial pneumonia with autoimmune features (IPAF): a clinical entity? Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Eosinophilic lung disease: clinical features of 25 patients Source: Eur Respir J 2006; 28: Suppl. 50, 237s Year: 2006 Distinct clinical phenotypes of airways disease: a primary-care clinician perspective Source: Eur Respir J 2010; 35: 459 Year: 2010 Is severe neutrophilic asthma a separate entity ?: Pro Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Towards individualised medicine for airways disease: identifying clinical phenotype groups Source: Eur Respir J 2012; 39: 1033-1034 Year: 2012 The progressive fibrotic phenotype in ILDs: can it be reliably recognised at baseline evaluation? Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases Year: 2019 Severe sarcoidosis: clinical features and management Source: Virtual Congress 2021 – Rare lung diseases 2021 Year: 2021 Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance? Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020 Year: 2020